Altimmune (ALT) Metrics: History & Chart

Altimmune, Inc.(ALT)

Biotechnology · Gaithersburg, MD

$2.68+0.01 (+0.28%)

Delayed quote: Oct 6, 2026, 2:45 PM EDT

About Altimmune, Inc.

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.

Gaithersburg, MD

57 employees

altimmune.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jerome Benedict Durso

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-9.80%
30D Total Return	-21.93%
YTD Total Return	-26.04%
1Y Total Return	-31.71%
3Y Total Return	+2.69%
5Y Total Return	-76.74%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	-26.04%
2025	-49.93%
2024	-35.91%
2023	-31.61%
2022	+79.59%
2021	-18.79%
2020

CAGR TTM	-31.59%
CAGR 3Y	+0.89%
CAGR 5Y	-25.30%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	0.13
PE Ratio Avg TTM	0.20
PE Ratio Avg 3Y	0.20
Current VS TTM Avg	-34.06%
Current VS 3Y Avg	-34.06%
Current VS 5Y Avg	-34.06%

All Metrics

ALT Valuation Metrics

ALT Stock Price Metrics

ALT Dividend Metrics

ALT Growth Rate Metrics

ALT Discounted Cash Flow Metrics

ALT Returns By Period

ALT Yearly Returns

ALT Average Annual Returns By Period (CAGR)

ALT Revenue Metrics

ALT PE Ratio Metrics

ALT PS Ratio Metrics

ALT PB Ratio Metrics

ALT Price to Free Cash Flow Ratio Metrics

ALT Debt to Equity Ratio Metrics

ALT PEG Ratio Metrics

ALT FCF Yield

ALT Earnings Yield

ALT EBITDA Yield

ALT OCF Yield

ALT EV/EBIT Ratio Metrics

ALT EV/EBITDA Ratio Metrics

ALT EV/Assets Ratio Metrics

ALT EV/Sales Ratio Metrics

ALT Current Ratio Metrics

ALT Quick Ratio Metrics

ALT ROIC Metrics

ALT Return on Assets Metrics

ALT Return on Equity Metrics

ALT Net Profit Margin Metrics

ALT Gross Profit Margin Metrics

ALT Tax Rate Metrics

PS Ratio	15972.09
PS Ratio Avg TTM	14908.47
PS Ratio Avg 3Y	10316.98
Current VS TTM Avg	+7.13%
Current VS 3Y Avg	+54.81%
Current VS 5Y Avg	+128.26%

PB Ratio	1.04
PB Ratio Avg TTM	1.67
PB Ratio Avg 3Y	2.47
Current VS TTM Avg	-37.85%
Current VS 3Y Avg	-57.93%
Current VS 5Y Avg	-54.64%

PFCF Ratio	0.27
PFCF Ratio Avg TTM	0.26
PFCF Ratio Avg 3Y	0.26
Current VS TTM Avg	+5.12%
Current VS 3Y Avg	+5.12%
Current VS 5Y Avg	+5.12%

Debt/Equity Ratio	0.08
Debt/Equity Ratio Avg TTM	0.11
Debt/Equity Ratio Avg 3Y	0.05
Current VS TTM Avg	-30.74%
Current VS 3Y Avg	+60.19%
Current VS 5Y Avg	+883.36%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	373.68%
FCF Yield Avg TTM	536.25%
FCF Yield Avg 3Y	536.25%
Current VS TTM Avg	-30.32%
Current VS 3Y Avg	-30.32%
Current VS 5Y Avg	-30.32%

Earnings Yield	760.46%
Earnings Yield Avg TTM	510.75%
Earnings Yield Avg 3Y	510.75%
Current VS TTM Avg	+48.89%
Current VS 3Y Avg	+48.89%
Current VS 5Y Avg	+48.89%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	0.89
Ev/Assets Ratio Avg TTM	1.21
Ev/Assets Ratio Avg 3Y	1.84
Current VS TTM Avg	-26.26%
Current VS 3Y Avg	-51.75%
Current VS 5Y Avg	-43.94%

Ev/Sales Ratio	15091.32
Ev/Sales Ratio Avg TTM	12786.98
Ev/Sales Ratio Avg 3Y	8694.17
Current VS TTM Avg	+18.02%
Current VS 3Y Avg	+73.58%
Current VS 5Y Avg	+162.52%

Current Ratio	26.78
Current Ratio Avg TTM	22.50
Current Ratio Avg 3Y	15.89
Current VS TTM Avg	+19.03%
Current VS 3Y Avg	+68.53%
Current VS 5Y Avg	+87.01%

Quick Ratio	26.78
Quick Ratio Avg TTM	22.50
Quick Ratio Avg 3Y	15.89
Current VS TTM Avg	+19.03%
Current VS 3Y Avg	+68.53%
Current VS 5Y Avg	+87.01%

ROIC	(19.47%)
ROIC Avg 3Y	(53.00%)
ROIC Avg 5Y	(48.24%)
Current VS 3Y Avg	+63.26%
Current VS 5Y Avg	+59.63%
Current VS 10Y Avg	+61.21%

ROA	(17.40%)
ROA Avg TTM	(8.23%)
ROA Avg 3Y	(11.47%)
Current VS TTM Avg	-111.35%
Current VS 3Y Avg	-51.75%
Current VS 5Y Avg	-51.24%

ROE	(19.35%)
ROE Avg TTM	(38.04%)
ROE Avg 3Y	(51.89%)
Current VS TTM Avg	+49.13%
Current VS 3Y Avg	+62.71%
Current VS 5Y Avg	+59.57%

Net Profit Margin	(296000.00%)
Net Profit Margin Avg TTM	(185684.62%)
Net Profit Margin Avg 3Y	(275385.60%)
Current VS TTM Avg	-59.41%
Current VS 3Y Avg	-7.49%
Current VS 5Y Avg	-47.70%

Gross Profit Margin	100.00%
Gross Pft Margin Avg TTM	(59780.00%)
Gross Pft Margin Avg 3Y	(574.51%)
Current VS TTM Avg	+100.17%
Current VS 3Y Avg	+117.41%
Current VS 5Y Avg	+104.62%

Tax Rate	12.51%
Tax Rate Avg 3Y	3.51%
Tax Rate Avg 5Y	3.51%
Current VS 3Y Avg	+256.13%
Current VS 5Y Avg	+256.13%
Current VS 10Y Avg	+115.01%